Recently Published Clinical Pharmacology Study Confirms Azilect® Selectively Inhibits MAO-B at Approved Doses
KANSAS CITY, Mo.—-Teva Neuroscience Inc. today announced the publication of a study demonstrating the selectivity of Azilect® for inhibition of MAO-B at the maximum approved dose of 1 mg/day.
Baba Ramdev -Yoga for Skin Diseases (Charm Rogon Ke Liye)